The move comes as FMC works to pay down $1 billion in debt through a series of asset sales and licensing agreements. A key component of this deleveraging strategy includes the divestiture of its commercial business in India. According to the company, these efforts are designed to stabilize its financial position while it evaluates the long-term future of the organization.

Navigating Post-Patent Competition

Beyond potential M&A activity, the firm is focused on maintaining the competitiveness of its legacy core portfolio. A primary challenge involves managing Rynaxypyr, its blockbuster insecticide, following the recent expiration of its patent. To counter generic pressure, the firm is prioritizing the commercialization of four new active ingredients.

Management believes that targeted investment in these new products could accelerate growth and improve overall margins. However, the company cautioned that the strategic review remains at an early stage, and there is no certainty that any transaction or formal agreement will materialize from the process.